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Objective: To investigate health-related quality of life (HRQOL) in patients affected by early systemic sclerosis (eSSc)
and to compare it with that of patients with undifferentiated connective tissue disease (UCTD).
Methods: At baseline, 31 eSSc and 35 UCTD patients underwent clinical evaluation, laboratory investigations,
nailfold videocapillaroscopy, echocardiography, and lung function tests. All patients and 40 controls, matched for
sex and age completed the Short Form-36 (SF-36) questionnaire and the Health Assessment Questionnaire
Disability Index (HAQ-DI).
Results: SF-36 scores were significantly lower in eSSc and UCTD patients than in healthy controls as regards the
following domains: physical component score (PCS), mental component score (MCS), physical functioning, role-
physical, bodily pain, general health and mental health. PCS was negatively correlated to the HAQ-DI (rho −0.59;
p = 0.0004) and ESR >20 mm/h (rho −0.58; p = 0.0006) in eSSc patients. No statistically significant correlation was
found between PCS, MCS and HAQ-DI in UCTD patients. Age, sex, disease duration, history of arthritis, low levels of
either C3 or C4, a low DLCO (carbon monoxide lung diffusion) and inversion of the E/A ratio were not correlated to
PCS and MCS in either eSSc or UCTD patients.
Conclusion: Many eSSc or UCTD patients perceive they have an impaired quality of life in both physical and
mental domains. This condition has to be taken into account by the clinicians involved in the care of these
patients.
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Systemic sclerosis (SSc) is an autoimmune rheumatic
disease of unknown etiology characterized by micro-
vascular injury and deposition of collagen and other
constituents of extracellular matrix in target organs [1].
It is associated with a reduced life expectancy [2], signifi-
cant functional disability [3-5] and depressive symptoms
[6]. Health-related quality of life (HRQOL), as assessed
by the Short Form-36 questionnaire (SF-36), is reduced
in SSc patients compared both with the general popula-
tion and with patients affected by such other common* Correspondence: michele_iudici@hotmail.com
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reproduction in any medium, provided the orchronic conditions as heart and lung diseases, diabetes
and arterial hypertension [7]. Previous studies that in-
vestigated HRQOL in patients with SSc were based on
patients who fulfilled either the American College of
Rheumatology (ACR) criteria for SSc [8] or LeRoy et al.’s
criteria [9] or both. They revealed that HRQOL is
impaired in patients suffering from each of the 2 main
SSc subsets, namely, limited cutaneous (lc) SSc and dif-
fuse cutaneous (dc) SSc, but that impairment is more
pronounced in patients with dcSSc i.e. the subset
characterized by a greater extent of skin sclerosis and
earlier and more severe involvement of target internal
organs [9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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high percentage of patients with Raynaud’s phenomenon
(RaP) and an SSc marker autoantibody and/or typical
SSc capillaroscopic findings and no manifestation other
than puffy fingers and/or arthritis, develop definite SSc
over time and proposed this condition be labeled “early
(e)SSc”. These patients, by definition, have no clinical
manifestation other than RaP. Thus far, no study has
evaluated HRQOL in patients with RaP and eSSc.
The aim of the present study was to investigate
HRQOL in patients affected by eSSc and to compare it
with that of patients with undifferentiated connective
tissue disease (UCTD) presenting only RaP and no other
symptoms and that of healthy controls to determine
whether the burden of secondary RaP and diagnosis of
either eSSc or UCTD affects quality of life.
Methods
Inclusion/exclusion criteria
Patients consecutively admitted to the outpatient clinic
of the Rheumatology Unit of the Second University of
Naples for the evaluation of RaP from January 1st 2007
to December 31st 2011 were enrolled in the study if they
fulfilled the following criteria: 1) Koenig et al.’s criteria
for early SSc [10] (i.e., RaP with a marker autoantibody
and/or a capillaroscopic scleroderma pattern without
any clinical manifestation other than RaP, puffy fingers
and/or present or past arthralgia/arthritis), or 2) Doria
et al.’s criteria [11] for UCTD (i.e., they had serum ANA
[antinuclear antibodies], but no marker autoantibody of
SSc or specific of any other connective tissue disease, no
scleroderma videocapillaroscopic findings or any clinical
manifestation pathognomonic of any other connective
tissue disease).
Patients fulfilling the American College of Rheumato-
logy criteria for SSc [8] and those presenting at least one
of the features of definite SSc according to Koenig et al.
[10] were excluded. The diagnosis of RaP was confirmed
if patients fulfilled LeRoy and Medsger’s criteria [9]
i.e., if a cold challenge induced bilateral, episodic bi- or
triphasic (pallor followed by dusky blueness and/or red-
ness) color changes of fingers. The study was approved
by the ethics committee of the Azienda Ospedaliera
Universitaria, Seconda Università di Napoli. All patients
agreed to participate to the study and provided written
informed consent.
Assessment of the patients
According to standard clinical practice and to ensure a
correct classification, all patients underwent: a detailed
history taking and a physical examination to identify the
above-listed exclusion features, and puffy fingers and
present or previous arthritis; routine laboratory inves-
tigations including cell blood count, urinalysis, BUN(blood urea nitrogen), ALT (alanine transaminase), AST
(aspartate transaminase), erythrocyte sedimentation rate
(ESR), serum protein electrophoresis and serum C3 and
C4 concentration; widefield nailfold videocapillaroscopy
(NVC) was carried out as described elsewhere [12] using
a videocapillaroscope (Videocap 25-DS Medica-Italy)
with optical probes of 200X. Stored images were re-
viewed by a physician (MI) experienced in NVC [13].
The degree of capillary enlargement on a scale of 0–3
and capillary loss (graded A–D) were investigated.
Megacapillaries (capillary enlargement ≥2) and/or avas-
cular areas (capillary loss grade ≥C) were considered a
scleroderma pattern [14,15]; a serum autoantibody pro-
file, carried out as described elsewhere [12] on sera
collected at the first visit, stored at −20°C and heated at
56°C for 30 min before testing, and including ANA, SSc
and other connective tissue disease marker autoanti-
bodies. ANA were considered positive when a diluition ≥
of 1:160 was registered, in absence of other known
conditions associated with ANA positivity (i.e. chronic B
or C hepatitis infection, autoimmune thyroid and he-
patic disorders, malignancies). Thorax X-ray, barium
esophageal X-ray and electrocardiogram were performed
to identify patients that should be excluded from the
study because of findings consistent with lung, esopha-
geal or cardiac SSc involvement. Moreover, at baseline
patients underwent B-mode echocardiography and lung
function tests, performed as described elsewhere [16,17].
Self-assessment questionnaires
Each patient and 40 healthy subjects recruited from the
administrative, nursing and medical staff of the Depart-
ment of Internal Medicine and matched for sex and age
with the enrolled patients, after giving a written informed
consent, were asked to complete self-administered ques-
tionnaires namely the Italian version of SF-36 [18] and
the Health Assessment Questionnaire-Disability Index
(HAQ-DI) [19]. The Italian version of SF-36 [18] consists
of 36 questions grouped into 8 domains physical func-
tioning, social functioning, role limitations related to
physical problems, role limitations related to emotional
problems, mental health, vitality, bodily pain and general
health perception. A score ranging from 0 (indicating the
worse health status) to 100 (indicating the best health sta-
tus) is assigned for each domain. Domain scores can be
summarized into a Physical Component Score (PCS) and
Mental Component Score (MCS) [18]. For these two sum-
mary scales, a score below 50 reflects a worse HRQOL
compared to the average of the general population [18].
HAQ-DI is a disease-specific, musculoskeletal-targeted
questionnaire designed to assess functional ability in
rheumatoid arthritis, the Italian version of which has been
validated [19]; it has been extensively used and validated
in SSc patients [3,4]. This questionnaire contains 20 items
Table 1 Demographic, clinical, serological and
capillaroscopic data of the eSSc and UCTD patients
Feature Early SSc UCTD P
n = 31 n = 35
Sex: F/M (n) 29/2 34/1 ns
Age; years (median; range) 41 (17–64) 40 (18–73) ns
RaP duration; years (median; range) 3 (1–24) 4 (0.5-30) ns
Puffy fingers (n;%) 3 (9.6) 0 (0) ns
History of arthritis (n;%) 0 (0) 4 (11.4) 0.052
ESR >20 mm/h (n;%) 5 (16.1) 3 (8.5) ns
Gammaglobulins > 1.5 g/dl (n;%) 2 (6.4) 2 (5.7) ns
C3 < 80 mg/dl or C4 < 15 mg/dl (n;%) 2 (6.4) 3 (8.5) ns
DLCO < 80% of predicted (n;%) 7 (22.5) 5/20 (25.0)* ns
E/A ratio < 1** (n;%) 2 (6.4) 1 (2.8) ns
ANA + (n;%) 30 (96.7) 35 (100) ns
SSc-marker antibodies + (n;%) 27 (87.0) 0 (0) -
ACA + (n;%) 20 (64.5) 0 (0) -
Anti-Scl-70 + (n;%) 6 (19.3) 0 (0) -
ESSG-AI > 3 (n;%) 0 (0) - -
NCM SSc pattern (n;%) 22 (70.9) 0 (0) -
Calcium channel blockers (n;%) 31 (100) 35 (100) ns
* In 20 out of 35 UCTD patients the DLCO was measured; **Not otherwise
explained.
All data are expressed as numbers and percentages (in brackets), except were
otherwise indicated.
SSc = systemic sclerosis; UCTD = undifferentiated connective tissue disease;
n = number; F = female; M = male; ns = not statistically significant; RaP = Raynaud’s
phenomenon; DLCO = carbon monoxide lung diffusion; E/A ratio <1, inverted ratio
between early (E)/late (atrial = A) ventricular filling velocity; ESR = erythrocyte
sedimentation rate; ANA = antinuclear antibodies; ACA = anticentromere antibodies;
ESSG-AI = European Scleroderma study group activity index; NCM = nailfold
capillary microscopy.
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highest scores in each domain are summed and then
divided by 8 to obtain the final HAQ-DI value, which
ranges from 0 (no disability) to 3 (severe disability).
Statistical analysis
Descriptive statistics were used to summarize the patients’
baseline characteristics. The chi-squared test was used for
comparison of proportions. The Mann–Whitney nonpara-
metric test was used for between-group comparisons.
Correlations among the SF-36 domains and HAQ-DI
scores, clinical parameters and disease activity were
investigated by Spearman’s correlation. Spearman’s coe-
fficient values were defined excellent (>0.91), good
(0.90-0.71), moderate (0.70-0.51), fair (0.50-0.31), or little
or none (<0.30).
Results
Sixty-six patients with RaP who fulfilled the entry criteria
were admitted to the outpatient clinic. The cohort
consisted of 63 women and 3 men, aged from 17 to 73 years
(median 41 years), with a disease duration from RaP onset
ranging from 0.5 to 30 years (median 3.5 years). Thirty-one
(46.9%) of them fulfilled the criteria for eSSc and 35
(53.1%) for UCTD. Table 1 shows the main demographic,
clinical, laboratory, and capillaroscopic features of the 31
eSSc and 35 UCTD patients. The two groups were similar
in terms of age, sex, RaP duration, ANA positivity and
prevalence of abnormal routine immune-inflammatory
parameters. All patients were taking the maximal tolerated
dose of calcium channel blockers (CCB – either nifedipine
20–60 mg/day or amlodipine 5–10 mg/day) to control
RaP. By definition, serum SSc-marker autoantibodies
(27/31 [87.0%] vs 0/35; p <0.0001) and a capillaroscopic
scleroderma pattern (22/31 [70.9%] vs 0/35; p <0.0001)
were detected only in eSSc patients. A history of arthritis
was found only in UCTD patients (4/35 [11.4%] vs 0/35)
(p = 0.052), whereas only 3 patients (all eSSc) had puffy
fingers (time of onset from RaP was 2 years in two patients
and three years in one patient).
The HAQ-DI and SF-36 scores in the two groups of
patients and in the controls are summarized in Table 2.
Statistically significant differences were found between
eSSc and UCTD patients and controls in the scores of
the following domains: PCS, MCS, physical functioning,
role-physical, bodily pain, general health and mental
health. There were no differences in any domain bet-
ween eSSc and UCTD patients.
At univariate analysis (Tables 3 and 4), PCS was nega-
tively correlated to HAQ-DI (rho −0.59; p = 0.0004) and
ESR >20 mm/h (rho −0.58; p = 0.0006) in eSSc patients.
No statistically significant correlation was found between
PCS, MCS and HAQ-DI in UCTD patients. Age, sex,
disease duration, history of arthritis, low levels of eitherC3 or C4, a low DLCO (carbon monoxide lung diffu-
sion) and inversion of the E/A ratio were not correlated
to PCS and MCS in eSSc or UCTD patients. The disease
duration in 5 UCTD patients was shorter than 3 years.
Considering these patients as pre-CTD (connective tis-
sue disease) and excluding them from the analysis, the
same results were obtained.
Discussion
This study was undertaken to assess the quality of life in
eSSc patients compared to that in UCTD and controls.
We found that HRQOL was impaired in both eSSc and
UCTD patients.
It would have been interesting to assess HRQOL
in patients with primary RaP, in whom an impaired
HRQOL has been recently pointed out by either SF-36
or EUROQoL 5 item questionnaire (EQ-5D) [20]. How-
ever, few patients with such a condition are referred to
our Rheumatologic tertiary centre.
Our results show that eSSc patients, who, by defini-
tion, experience only Raynaud’s phenomenon but no
Table 2 HAQ-DI and SF-36 values in eSSc, UCTD patients and healthy subjects
SF-36 and HAQ-DI scores eSSc UCTD Controls P1 P2 P3
n = 31 n = 35 n = 40
PCS (Median; Range) 51 (28–57) 48 (32–58) 59 (46–66) 0.762 <0.001 <0.001
MCS (Median; Range) 47 (18–67) 48 (25–63) 54 (20–76) 0.943 0.020 0.014
HAQ-DI (Median; Range) 0 (0–1) 0 (0–1) 0 (0–0.25) 0.572 0.043 0.102
Physical functioning (Median; Range) 90 (30–100) 85 (50–100) 100 (90–100) 0.852 <0.001 <0.001
Role-physical (Median; Range) 100 (0–100) 100 (0–100) 100 (50–100) 0.607 0.020 0.017
Bodily pain (Median; Range) 64 (22–100) 41 (41–100) 84 (41–100) 0.378 0.018 <0.001
General health (Median; Range) 61 (10–97) 50 (25–92) 76 (46–100) 0.232 <0.001 <0.001
Vitality (Median; Range) 65 (15–95) 55 (25–100) 65 (30–100) 0.328 0.145 0.0071
Social functioning (Median; Range) 75 (12–100) 75 (25–100) 84 (12–100) 0.210 0.406 0.892
Role-emotional (Median; Range) 66 (0–100) 100 (0–100) 100 (0–100) 0.625 0.314 0.456
Mental health (Median; Range) 68 (8–100) 64 (28–100) 84 (4–100) 0.792 0.0045 0.0011
eSSc = early SSc; UCTD = undifferentiated connective tissue disease; P1 = eSSc vs UCTD; P2 = eSSc vs controls; P3 = UCTD vs controls; PCS = physical component
summary score; MCS =mental component summary score; HAQ-DI = Health assessment questionnaire–disability index.
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paired physical and mental quality of life, as happens in
other subgroups of SSc patients [7,21]. Here we show
that disability and an increase in ESR levels are nega-
tively associated with physical health status. In these
patients the only functional impairment was the RaP
and/or the presence of puffy hands (this latter condition
in only 3 eSSc patients).
Since HRQOL has been reported to be impaired in
patients with primary RaP, one could postulate that the
impairment in HRQOL in SSc and UCTD patients might
be ascribed to RaP itself. Such assumption, however, would
not totally justify this condition, especially considering that
these patients were taking the maximum tolerated dose ofTable 3 Correlations among clinic and laboratory features
and PCS and MCS scores in eSSc patients
Clinical and laboratory features PCS (rho; P) MCS (rho; P)
Age −0.15 (0.413) 0.481 (0.060)
Sex F −0.19 (0.283) 0.007 (0.968)
Disease duration −0.19 (0.281) 0.0049 (0.979)
History of arthritis 0 0
ESR >20 mm/h −0.58 (0.0006) −0.049 (0.793)
Gammaglobulins > 1.5 g/dl −0.06 (0.723) 0.117 (0.528)
C3 < 80 mg/dl or C4 < 15 mg/dl 0.133 (0.475) 0.112 (0.547)
Low DLCO (<80% of predicted) 0.056 (0.763) 0.142 (0.444)
E/A ration < 1 −0.09 (0.607) 0.027 (0.883)
HAQ-DI −0.59 (0.0004) −0.298 (0.103)
Active disease 0 0
PCS = physical component summary score; MCS =mental component summary
score; ESR = erythrocyte sedimentation rate; DLCO = carbon monoxide lung
diffusion; E/A ratio <1, inverted ratio between early (E)/late (atrial = A)
ventricular filling velocity; HAQ-DI = Health assessment questionnaire–disability
index.vasodilators prescribed to decrease the frequency and du-
ration of RaP attacks and that most of them stated to have
a good control of their RaP condition.
Given the low burden of disability registered, we can
postulate that the clinical measures commonly assessed
in eSSc and UCTD do not completely account for the
poor quality of life perceived by these patients and this
could be explained in different ways.
First of all, a great difference between the assessment
of the disease severity and HRQOL has to be taken into
account: in fact, the former is made through a pre-
specified combination of clinical, laboratory and instru-
mental exams which might overlook some aspects of the
disease influencing the health status, that is investigated,
as known, by self-report questionnaires.Table 4 Correlations among clinic and laboratory features
and PCS and MCS scores in UCTD patients
Clinical and laboratory features PCS (rho; P) MCS (rho; P)
Age −0.03 (0.831) 0.08 (0.607)
Sex F −0.02 (0.883) 0.223 (0.201)
Disease duration 0.166 (0.339) 0.199 (0.246)
History of arthritis 0.104 (0.561) 0.136 (0.433)
ESR >20 mm/h −0.290 (0.085) 0.303 (0.070)
Gammaglobulins > 1.5 g/dl −0.231 (0.823) −0.178 (0.623)
C3 < 80 mg/dl or C4 < 15 mg/dl −0.176 (0.454) −0.234 (0.234)
Low DLCO (<80% of predicted) −0.08 (0.720) 0.185 (0.446)
E/A ratio < 1 −0.10 (0.561) 0.061 (0.728)
HAQ-DI −0.44 (0.070) −0.060 (0.725)
PCS = physical component summary score; MCS =mental component summary
score; ESR = erythrocyte sedimentation rate; DLCO = carbon monoxide lung
diffusion; E/A ratio <1, inverted ratio between early (E)/late (atrial = A)
ventricular filling velocity; HAQ-DI = Health assessment questionnaire–disability
index.
Iudici et al. Health and Quality of Life Outcomes 2013, 11:23 Page 5 of 6
http://www.hqlo.com/content/11/1/23Moreover, a recent study of HRQOL in SSc patients
suggested that the most important determinants of phy-
sical and mental health are the patient’s cognitive repre-
sentations of the illness [22]. Arat et al. [22] observed that
the fear of clinical consequences and the tendency to attri-
bute each physical complaint to SSc (“illness identity”), are
the main contributors to physical health, whereas the
emotional responses to personal representation of the
disease are the main contributors to mental health. In
addition to illness perception, the use of various strategies
to cope better with the disease is related to physical and
mental health [22].
Given the above observations, it is conceivable that in
eSSc and UCTD patients similar psychological mechanisms
might contribute, together with the disease –related
symptoms to the worse quality of life. Unfortunately, one of
the shortcomings of our study is that we did not include
instruments that measure psychosocial factors, and so no
conclusion about the relationships between psychosocial
factors and HRQOL can be drawn.
ANA positivity in patients with RaP has long been
known to be a factor predictive of the development of a
CTD [23,24]. In that regard, the absence of any signifi-
cant difference between patients with (eSSc) and without
(UCTD) marker autoantibody would suggest that the
presence of an autoimmune RaP might be sufficient to
affect HRQOL.
This study has some limitations. First of all, the num-
ber of patients enrolled is relatively low so that a larger
sample is required to confirm these results. Moreover, as
already stated it would have been intriguing to assess the
HRQOL also in patients affected by a primary RaP, but
unfortunately few patients with such a condition are re-
ferred to our centre. Finally, our data do not allow us to
identify other determinants of the reduced quality of life
in both mental and physical domains, apart from those
described.
In conclusion, we assessed HRQOL in eSSc and
UCTD patients and looked for associations between
clinical features and health status perception. Although
the correlations observed do not reflect a causal rela-
tionship, our results might be useful to identify targets
of intervention. Our data would suggest that also these
patients experience an impaired quality of life in both
physical and mental domains. This condition has to be
taken into account by the clinicians involved in their
care. In the absence of a therapy able to definitively
block injury to lungs, joints and other internal organs,
further studies are needed to completely identify the
factors that contribute to the poor health status in eSSc
and UCTD patients.
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